Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cellectis

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

AZ faces early competition to Nexium in the US

Korea's Hanmi and Amneal Pharmaceuticals launches first generic rival

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

- PMLiVE

Good news for AZ on gout candidate lesinurad

Phase III trial backs planned filing in 2014

- PMLiVE

AZ donates Brixham lab to Plymouth University

Will create global research and education facility

- PMLiVE

AZ wins EU approval for four-strain flu vaccine

Fluenz Tetra offers competition to GSK’s Influsplit Tetra/Fluarix Tetra

Roche - Basel

Roche signs $1bn-plus cancer deal with Molecular Partners

Partnership could create new type of drug conjugate similar to ADCs

- PMLiVE

AZ said to be eyeing Forest takeover bid

Financial Times says pharma companies are in early negotiations

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links